国家综合癌症网络财务利益冲突政策的执行趋势。

IF 3.4 Q2 ONCOLOGY JNCI Cancer Spectrum Pub Date : 2024-11-26 DOI:10.1093/jncics/pkae120
Niloufar Saririan, Dedipya Bhamidipati, Pranam Dey, Sonia Persaud, Nirjhar Chakraborty, Sara Tabatabai, Grace Gallagher, Niti U Trivedi, Aaron P Mitchell
{"title":"国家综合癌症网络财务利益冲突政策的执行趋势。","authors":"Niloufar Saririan, Dedipya Bhamidipati, Pranam Dey, Sonia Persaud, Nirjhar Chakraborty, Sara Tabatabai, Grace Gallagher, Niti U Trivedi, Aaron P Mitchell","doi":"10.1093/jncics/pkae120","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The National Comprehensive Cancer Network (NCCN) financial conflict of interest (FCOI) policy sets dollar maximums for panelists, but violations may occur.</p><p><strong>Methods: </strong>We studied NCCN Guidelines panelists for the 20 most prevalent cancers, 2013-2022. We included panelists with ≥1 calendar year of service (\"current panelists\") and those who began service during the study period (\"new panelists\"); NCCN FCOI policy limits ($20,000 from any single company or $50,000 across all companies) applies to both groups. Industry payments were obtained from Open Payments and mapped manually via NPI. We calculated industry payments received, excluding the same payment categories as does NCCN (research, meals, travel & lodging). We estimated whether panelists received payments exceeding NCCN limits (\"violation\"). As a proxy for whether panelists were subsequently disqualified as stipulated, we measured continued service for ≥1 calendar year (\"retention\") subsequent to an estimated violation. We analyzed retention before and after 2016, due to increased scrutiny on NCCN FCOI in 2016.</p><p><strong>Results: </strong>The annual proportion of current panelists with estimated violations ranged between 0.5% (2020) and 5.8% (2016). Among panelists who did vs did not have violations, retention was 83.6% vs 88.5% during 2014-15 (OR 0.55, 95%CI: 0.26-1.31) and 46.6% vs 89.4% during 2017-2020 (OR 0.10, 95%CI: 0.06-0.17). Among new panelists, 2.7% (5/185) had prior-year violations during 2014-15, as did 5.5% (18/330) during 2017-21.</p><p><strong>Conclusions: </strong>Each year, a small portion of panelists receive industry payments exceeding NCCN limits. Since 2016, the likelihood that such panelists will continue to serve has decreased substantially.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Trends in Enforcement of National Comprehensive Cancer Network Financial Conflict of Interest Policy.\",\"authors\":\"Niloufar Saririan, Dedipya Bhamidipati, Pranam Dey, Sonia Persaud, Nirjhar Chakraborty, Sara Tabatabai, Grace Gallagher, Niti U Trivedi, Aaron P Mitchell\",\"doi\":\"10.1093/jncics/pkae120\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The National Comprehensive Cancer Network (NCCN) financial conflict of interest (FCOI) policy sets dollar maximums for panelists, but violations may occur.</p><p><strong>Methods: </strong>We studied NCCN Guidelines panelists for the 20 most prevalent cancers, 2013-2022. We included panelists with ≥1 calendar year of service (\\\"current panelists\\\") and those who began service during the study period (\\\"new panelists\\\"); NCCN FCOI policy limits ($20,000 from any single company or $50,000 across all companies) applies to both groups. Industry payments were obtained from Open Payments and mapped manually via NPI. We calculated industry payments received, excluding the same payment categories as does NCCN (research, meals, travel & lodging). We estimated whether panelists received payments exceeding NCCN limits (\\\"violation\\\"). As a proxy for whether panelists were subsequently disqualified as stipulated, we measured continued service for ≥1 calendar year (\\\"retention\\\") subsequent to an estimated violation. We analyzed retention before and after 2016, due to increased scrutiny on NCCN FCOI in 2016.</p><p><strong>Results: </strong>The annual proportion of current panelists with estimated violations ranged between 0.5% (2020) and 5.8% (2016). Among panelists who did vs did not have violations, retention was 83.6% vs 88.5% during 2014-15 (OR 0.55, 95%CI: 0.26-1.31) and 46.6% vs 89.4% during 2017-2020 (OR 0.10, 95%CI: 0.06-0.17). Among new panelists, 2.7% (5/185) had prior-year violations during 2014-15, as did 5.5% (18/330) during 2017-21.</p><p><strong>Conclusions: </strong>Each year, a small portion of panelists receive industry payments exceeding NCCN limits. Since 2016, the likelihood that such panelists will continue to serve has decreased substantially.</p>\",\"PeriodicalId\":14681,\"journal\":{\"name\":\"JNCI Cancer Spectrum\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2024-11-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JNCI Cancer Spectrum\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1093/jncics/pkae120\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JNCI Cancer Spectrum","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/jncics/pkae120","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:美国国立综合癌症网络(NCCN)的财务利益冲突(FCOI)政策为专家组成员设定了金额上限,但违规行为可能会发生:我们研究了 2013-2022 年 20 种最常见癌症的 NCCN 指南专家组成员。我们纳入了服务时间≥1 个日历年的专家组成员("现任专家组成员")和在研究期间开始服务的专家组成员("新任专家组成员");NCCN FCOI 政策限额(来自任何一家公司的 20,000 美元或来自所有公司的 50,000 美元)适用于这两组专家组成员。行业付款来自 Open Payments,并通过 NPI 人工映射。我们计算了收到的行业付款,但不包括与 NCCN 相同的付款类别(研究、餐饮、差旅和住宿)。我们估算了专家组成员收到的付款是否超过了 NCCN 的限额("违规")。作为专家组成员随后是否按规定被取消资格的替代指标,我们衡量了估计违规行为发生后持续服务≥1 个日历年("保留")的情况。由于 2016 年对 NCCN FCOI 的审查力度加大,我们对 2016 年之前和之后的保留率进行了分析:估计违规的现有专家组成员的年度比例介于 0.5%(2020 年)和 5.8%(2016 年)之间。在有违规行为与无违规行为的专家组成员中,2014-15年期间的留任率为83.6% vs 88.5%(OR 0.55,95%CI:0.26-1.31),2017-2020年期间的留任率为46.6% vs 89.4%(OR 0.10,95%CI:0.06-0.17)。在新的专家组成员中,2014-15 年期间有 2.7%(5/185)的人有上一年的违规行为,2017-21 年期间有 5.5%(18/330)的人有上一年的违规行为:每年都有一小部分专家组成员收到的行业报酬超过了NCCN的限额。自 2016 年以来,此类专家组成员继续任职的可能性大幅下降。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Trends in Enforcement of National Comprehensive Cancer Network Financial Conflict of Interest Policy.

Background: The National Comprehensive Cancer Network (NCCN) financial conflict of interest (FCOI) policy sets dollar maximums for panelists, but violations may occur.

Methods: We studied NCCN Guidelines panelists for the 20 most prevalent cancers, 2013-2022. We included panelists with ≥1 calendar year of service ("current panelists") and those who began service during the study period ("new panelists"); NCCN FCOI policy limits ($20,000 from any single company or $50,000 across all companies) applies to both groups. Industry payments were obtained from Open Payments and mapped manually via NPI. We calculated industry payments received, excluding the same payment categories as does NCCN (research, meals, travel & lodging). We estimated whether panelists received payments exceeding NCCN limits ("violation"). As a proxy for whether panelists were subsequently disqualified as stipulated, we measured continued service for ≥1 calendar year ("retention") subsequent to an estimated violation. We analyzed retention before and after 2016, due to increased scrutiny on NCCN FCOI in 2016.

Results: The annual proportion of current panelists with estimated violations ranged between 0.5% (2020) and 5.8% (2016). Among panelists who did vs did not have violations, retention was 83.6% vs 88.5% during 2014-15 (OR 0.55, 95%CI: 0.26-1.31) and 46.6% vs 89.4% during 2017-2020 (OR 0.10, 95%CI: 0.06-0.17). Among new panelists, 2.7% (5/185) had prior-year violations during 2014-15, as did 5.5% (18/330) during 2017-21.

Conclusions: Each year, a small portion of panelists receive industry payments exceeding NCCN limits. Since 2016, the likelihood that such panelists will continue to serve has decreased substantially.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
JNCI Cancer Spectrum
JNCI Cancer Spectrum Medicine-Oncology
CiteScore
7.70
自引率
0.00%
发文量
80
审稿时长
18 weeks
期刊最新文献
Trends in Enforcement of National Comprehensive Cancer Network Financial Conflict of Interest Policy. Cancer Clinical Trial Participation: A Qualitative Study of Black/African American Communities' and Patient/Survivors' Recommendations. Social determinants of health and variability in treatment for patients with early-stage Non-Small Cell Lung Cancer. Inequities in palliative care delivery to patients with HIV and Stage IV cancers in the US (2004-2020). Trilaciclib prior to FOLFOXIRI/bevacizumab for patients with untreated metastatic colorectal cancer: phase 3 PRESERVE 1 trial.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1